DUBLIN–(BUSINESS WIRE)–Research and Markets (researchandmarkets.com/research/3b0638/prostate_cancer) has announced the addition of GlobalData ‘s new report “Prostate Cancer – BRIC Drug Forecasts and Treatment Analysis to 2020″ to their offering.

“Prostate Cancer – BRIC Drug Forecasts and Treatment Analysis to 2020”

our pharmaceutical report, Prostate Cancer – Brazil, Russia, India and China (BRIC) Drug Forecasts and Treatment Analysis to 2020 is an essential source of information and analysis on the prostate cancer therapeutics market in the emerging BRIC countries. the report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. it identifies and analyzes the key trends shaping and driving the prostate cancer therapeutics market in Brazil, Russia, India and China. it analyzes the treatment usage patterns in the BRIC prostate cancer therapeutics market. the report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. the report provides valuable insights into the pipeline products within the global prostate cancer sector. it quantifies the unmet need in the BRIC prostate cancer therapeutics market, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by our team of industry experts.

the scope of the report includes:

the report will enhance your decision making capability. it will allow you to:

• Develop business strategies and perform superior market quantification analysis by – Understanding the trends shaping and driving the Japanese prostate cancer therapeutics market. – Understanding the treatment preferences of physicians according to disease state and across treatment flow. – Assessing market sizing, forecasts and quantified growth opportunities in the BRIC prostate cancer therapeutics market up to 2020. – Quantifying the patient population in the BRIC countries to better design product pricing and launch plans.
• Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by – Performing benchmarking analysis and growth opportunities against currently marketed products. – Identifying market entry points based on safety, efficacy and pricing parameters. – Assessing competitiveness of products in market by understanding the strength and weakness of the current competition.
• Develop and design your in-licensing and out-licensing strategies by – Taking a comprehensive look of at the disease pipeline and identifying the most promising paradigm shifting products. – Assessing the strength of pipeline based on first-in-class, me-too and generic products and their lifecycle management.
• Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.

Prostate Cancer – Brazil, Russia, India and China (BRIC) Drug Forecasts and Treatment Analysis to 2020 is an essential source of information and analysis on the prostate cancer therapeutics market in the emerging BRIC countries. the report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. it identifies and analyzes the key trends shaping and driving the prostate cancer therapeutics market in Brazil, Russia, India and China. it analyzes the treatment usage patterns in the BRIC prostate cancer therapeutics market. the report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. the report provides valuable insights into the pipeline products within the global prostate cancer sector. it quantifies the unmet need in the BRIC prostate cancer therapeutics market, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

the Prostate Cancer Therapeutics Market was Driven by the Growth in Patient Volume and Annual Cost of Hormone-refractory Prostate Cancer Therapy

the authors analysis finds that the prostate cancer therapeutics market in BRIC (Brazil, Russia, India and China) is attractive and is primarily driven by the growth in the hormone-refractory prostate cancer therapeutics market. the growth in the number of total patients receiving treatment and increase in the annual cost of hormone-refractory prostate cancer therapy is expected to offset the impact of generic erosion in hormone-dependent prostate cancer therapy. the patient volume was driven by growth in treatment usage patterns such as diseased population, treatment seeking population, diagnosis population and prescription population. the annual cost of prostate cancer therapy between 2001 and 2009 was driven by increased uptake of chemotherapy using Taxotere. Expected launch of new therapies such as Provenge (sipuleucel-T) and Jevtana (cabazitaxel) will further drive the annual cost of therapy.

Hormone therapy using combination of hormone therapies such as LHRH agonists and androgen receptor antagonists is a prominent treatment regime. Taxotere is the current standard of care for patients that stop responding to hormone therapy. the introduction of new therapies for metastatic prostate cancer is expected to expand the market further.

• 1 Overview
• 2 Disease Overview
• 3 Market Characterization
• 4 Competitor Assessment
• 5 Pipeline Assessment
• 6 Unmet need and Target Product Profile
• 7 Strategic Assessment
• 8 Company Profiles
• 9 M&A Analysis
• 10 Appendix

Companies Mentioned:

For more information visit researchandmarkets.com/research/3b0638/prostate_cancer.

Press Release Source: Reportlinker on Tuesday November 23, 2010, 1:46 pm EST

NEW YORK, Nov. 23, 2010 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue:

Prostate Cancer – Germany Drug Forecasts and Treatment Analysis to 2020

reportlinker.com/p0332251/Prostate-Cancer—Germany-Drug-Forecasts-and-Treatment-Analysis-to-2020.html

Prostate Cancer – Germany Drug Forecasts and Treatment Analysis to 2020

Summary

GlobalData’s pharmaceutical report, “Prostate Cancer – Germany Drug Forecasts and Treatment Analysis to 2020″. The report is an essential source of information and analysis on the German prostate cancer therapeutics market. The report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. It identifies and analyzes the key trends shaping and driving the German prostate cancer therapeutics market, and analyzes the treatment usage patterns. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global prostate cancer sector. It quantifies the unmet need in the German prostate cancer therapeutics market, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The scope of the report includes:

- An overview of prostate cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.

- Annualized German prostate cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, forecast for 11 years to 2020.

- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.

- Competitor assessment including drug launch analysis and drug sales forecasts.

- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM (Life Cycle Management) activities and drug sales forecast.

- Analysis of unmet need in the market and target product profiles including opportunity for target products.

- Technology trends analytic framework to assess the strength of the pipeline.

- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, tyrosine kinase inhibitor, angiogenesis inhibitors and others.

- An overview of the most promising drugs including clinical study details, efficacy, safety, collaboration agreements, marketing rights and launch analysis.

- Analysis of the current and future market competition in the German Prostate Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Sanofi-aventis, Pfizer, inc., AstraZeneca PLC, Bristol-Myers Squibb, Medivation, Takeda Pharmaceuticals and Dendreon Corporation.

- Analysis of licensing agreements during 2004-2010 in the prostate cancer therapeutics market. Merger and Acquisition (M&A analysis) which includes M&A deals by size and geography.

- Strategic assessment of the market through market impact analysis, future market scenario and company analysis.

- Direct quotes from key opinion leaders (KOL) or physicians in the prostate cancer therapeutics market in Germany.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

- Develop business strategies and perform superior market quantification analysis by

- Understanding the trends shaping and driving the German prostate cancer therapeutics market.

- Understanding the treatment preferences of physicians for each disease state and across treatment flow.

- Accessing market sizing forecasts and quantified growth opportunities in the German prostate cancer therapeutics market up to 2020.

- Quantifying the patient population in the German to better design product pricing and launch plans.

- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by

- Performing benchmarking analysis and growth opportunities against currently marketed products.

- Identifying market entry points based on safety, efficacy, and pricing parameters.

- Assessing competitiveness of products in the market by understanding the strengths and weaknesses of current competition.

- Develop and design your in-licensing and out-licensing strategies by

- taking a comprehensive look at the disease pipeline and identifying the most promising paradigm-shifting products.

- Assessing the strength of pipeline based on first-in-class, me-too and generic products and their lifecycle management.

- Track drug sales in the German prostate cancer therapeutics market from 2001 to 2020.

- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.

- What’s the next big thing in the German prostate cancer therapeutics market landscape? Identify, understand and capitalize.

1 Table of contents 4

1.1 List of Tables 7

1.2 List of Figures 8

2 Disease Overview 10

2.1.1 TNM (Tumor, Nodes, Metastasis) Staging system 10

2.1.2 Jewett-Whitmore system 11

2.4.1 Localized or Locally Advanced Prostate Cancer 12

2.4.2 Metastatic Prostate Cancer 13

2.5.1 Digital Rectal Examination 13

2.5.2 Prostate Specific Antigen Test 13

2.5.3 Transrectal Ultrasound 14

2.5.4 Prostate Biopsy 14

2.7.1 Watchful Waiting 15

2.7.2 Radiation therapy 15

2.7.4 Hormone therapy 17

2.7.5 Chemotherapy Options 18

2.7.6 other Treatments being Studied 19

2.8 Treatment Guidelines 19

3 Market Characterization 20

3.1.2 Drivers and Barriers 26

3.1.3 Impact on the Market 28

3.1.6 Pricing & Reimbursements 39

4 Competitor Assessment 40

4.1 Strategic Competitor Assessment 40

4.1.2 Benchmarking 40

4.1.3 Current Competitor Assessment 44

4.2 Launch Analysis and Sales Forecasts 45

4.3 Product Profiles 46

4.3.1 Taxotere (docetaxel) 47

4.3.2 Casodex (Bicalutamide) 50

4.3.3 Zoladex (Goserelin) 55

4.3.4 Eligard (leuprolide acetate) 57

4.3.5 Firmagon (degarelix) 62

4.3.6 Novantrone (Mitoxantrone hydrochloride) 64

4.3.7 Emcyt (estramustine) 66

4.3.8 Trelstar (triptorelin) 68

4.3.10 Delestrogen 71

4.3.12 Estrace tablet 73

4.3.16 Sales Forecast for Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol 76

5 Pipeline Assessment 77

5.2 Pipeline Analysis by Phase of Development 78

5.3 Pipeline by Mechanism of Action 79

5.4 Strategic Pipeline Assessment 80

5.4.1 Technology Trends Analytical Framework 80

5.5 Trends in Prostate Cancer Pipeline 81

5.5.1 more Clarity on the Origin of Prostate Cancer will help in Identifying novel Targets for Prostate Cancer Drugs 81

5.5.2 Molecules with novel Mechanism of Action Strengthening Prostate Cancer Pipeline 81

5.5.3 Failure of Key Molecules to Achieve Positive Results in Phase III Development 81

5.6 Partners in Research and Development 82

5.6.1 Licensing Agreements by Phase of Development 82

5.6.2 Licensing Agreements by Geography 85

5.6.3 Licensing Agreements: Technology Licensing Agreements in Prostate Cancer 85

5.7 most Promising Drugs’ Profiles 86

5.7.1 Provenge (sipuleucel-T) 87

5.7.2 Jevtana (cabazitaxel) 90

5.7.3 Aflibercept (VEGF Trap) 91

5.7.5 Abiraterone Acetate (CB7630) 96

5.7.6 Zibotentan (ZD4054) 98

5.7.7 Sprycel (dasatinib) 100

5.8 Prostate Cancer Pipeline – Pre-clinical Phase 105

5.9 Prostate Cancer Pipeline – Phase I 106

5.10 Prostate Cancer Pipeline – Phase II 108

5.11 Prostate Cancer Pipeline – Phase III 115

5.12 Key Takeaway 116

6 Unmet need and Target Product Profile 117

6.1 Unmet need 119

6.1.1 Hormone-independent Metastatic Prostate Cancer Therapy 119

6.1.2 Hormone-dependent Metastatic Prostate Cancer Therapy 120

6.2 Opportunity for Target Product 121

6.3 Target Product Profile 123

6.3.1 Ideal Characteristics 123

6.3.2 Target Product Description 124

7 Strategic Assessment 125

7.1 Key Events Impacting the Future Market 125

7.2 Market Impact Analysis 126

7.3 Future Market Scenario 126

7.4 Company Analysis 127

7.4.1 Market Leadership 127

7.4.2 Future Players in the Market 128

8 Company Profiles 129

8.1 Sanofi-aventis 129

8.1.1 Business Description 129

8.1.2 Financial Overview 131

8.1.3 SWOT Analysis 131

8.1.4 Oncology Focus 136

8.2 Pfizer inc. 136

8.2.1 Business Description 136

8.2.2 Financial Overview 137

8.2.3 SWOT Analysis 138

8.2.4 Oncology Focus 144

8.3.1 Business Description 145

8.3.2 Financial Overview 147

8.3.3 SWOT Analysis 147

8.3.4 Oncology Focus 151

8.4 Bristol-Myers Squibb 152

8.4.1 Business Description 152

8.4.2 Financial Overview 153

8.4.3 SWOT Analysis 154

8.4.4 Oncology Focus 159

8.5.1 Business Description 160

8.5.2 SWOT Analysis 161

8.5.3 Oncology Focus 164

8.6 Takeda Pharmaceuticals 164

8.6.1 Business Description 164

8.6.2 SWOT Analysis 165

8.7 Dendreon Corporation 166

8.7.1 Business Description 166

8.7.2 SWOT Analysis 167

8.8 Johnson and Johnson 170

8.8.1 Business Description 170

8.8.2 SWOT Analysis 171

8.8.3 Oncology Focus 178

8.9 Auron Healthcare GmbH 179

8.9.1 Business Description 179

8.10 Oncogenex Pharmaceuticals, inc. 179

8.10.1 Business Description 179

8.11.1 Business Description 179

8.12 GTx, inc. 180

8.12.1 Business Description 180

8.13 GlaxoSmithKline plc. 180

8.13.1 Business Description 180

8.13.2 Financial Overview 181

8.13.3 SWOT Analysis 181

8.13.4 Oncology Focus 187

9.1 Key Highlights 189

9.2 Key Deals’ Analysis 190

9.2.1 Johnson & Johnson Acquires Cougar Biotechnology 190

9.2.2 Endo Pharmaceuticals Acquires Indevus Pharmaceuticals 190

9.2.3 Tolmar Holding Acquires QLT USA from QLT 191

9.2.4 Biomarin Pharmaceutical to acquire Lead therapeutics 191

9.2.5 Isis Pharmaceuticals Reacquires Rights to Cancer Drug from Eli Lilly & co. 191

9.2.6 Quest PharmaTech Acquires Late-stage Immunotherapeutic Antibody Pipeline from Paladin Labs 191

9.2.7 VaxOnco Acquires Rights to Onyvax-P Cell Vaccine from Onyvax 191

9.2.8 GPC Biotech Merges with Agennix 191

9.2.9 Eli Lilly Acquires ImClone 192

9.2.10 BBM Holdings Acquires YM BioSciences 192

9.2.11 Sagent Pharmaceuticals Acquires Injectable Generic Drug Applications of Spectrum Pharmaceuticals 192

9.3 M&A Deals by Geography 193

9.4 M&A Deals by Deal Size 193

10 Expert Opinion 194

11.1 Market Definitions 195

11.2 Abbreviations 195

11.3 Research Methodology 197

11.3.2 Secondary Research 198

11.3.3 Forecasting 198

11.3.4 Primary Research 201

11.3.5 Expert Panel validation 201

11.3.6 Contact us 201

11.3.7 Disclaimer 201

1.1 List of Tables

Table 1: Prostate Cancer Therapeutics Market, Global, Staging of the Prostate Cancer, 2010 11

Table 2: Prostate Cancer, Global, Age Related PSA Levels (ng/ml), 2010 14

Table 3: Prostate Cancer Therapeutics Market, Germany, Sales Value ($m), 2001-2009 20

Table 4: Prostate Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2001-2009 22

Table 5: Prostate Cancer Therapeutics Market, Germany, Patient Volume (’000s), 2001-2009 23

Table 6: Prostate Cancer Therapeutics Market, Germany, Treatment Usage Patterns (’000s), 2001-2009 24

Table 7: Prostate Cancer Therapeutics Market, Germany, Sales Value ($m), 2009-2020 29

Table 8: Prostate Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2009-2020 30

Table 9: Prostate Cancer Therapeutics Market, Germany, Patient Volume (’000s), 2009-2020 31

Table 10: Prostate Cancer Therapeutics Market, Germany, Treatment Usage Patterns (’000s), 2009-2020 32

Table 11: Prostate Cancer Therapeutics Market, Germany, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2010 36

Table 12: Prostate Cancer Therapeutics Market, Germany, Hormone-refractory Prostate Cancer Drug Sales ($m), 2011-2020 36

Table 13: Prostate Cancer Therapeutics Market, Germany, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2010 38

Table 14: Prostate Cancer, Germany, Hormone-dependent Prostate Cancer Drug Sales ($m), 2011-2020 38

Table 15: Prostate Cancer, Global, Clinical Endpoints for Benchmarking, 2010 41

Table 16: Prostate Cancer, Global, Chemotherapy, Safety Profile of Standard Care Treatment, 2010 42

Table 17: Prostate Cancer, Global, Hormone Therapy, Safety Profile of Standard Care Treatment, 2010 43

Table 18: Prostate Cancer, Germany, Benchmarking Major Marketed Products, 2010 46

Table 19: Prostate Cancer, Global, Casodex, Incidence of Adverse Effects, 2010 51

Table 20: Prostate Cancer, Global, Eligard, Effect on PSA Level, 2010 58

Table 21: Prostate Cancer, Global, Eligard, Incidence of Adverse Effects, 2010 59

Table 22: Prostate Cancer, Global, Eligard, Regulatory Approval by Region 60

Table 23: Prostate Cancer, Global, Licensing Agreements, 2009-2010 84

Table 24: Prostate Cancer, Global, Technology Licensing Agreements Description, 2010 86

Table 25: Prostate Cancer, Global, most Promising Drugs under Clinical Development, 2010 86

Table 26: Prostate Cancer, Global, Pre-clinical Phase Pipeline, August 2010 105

Table 27: Prostate Cancer, Global, Phase I Pipeline, August 2010 106

Table 28: Prostate Cancer, Global, Phase II Pipeline, August 2010 108

Table 29: Prostate Cancer, Global, Phase III Pipeline, August 2010 115

Table 30: Prostate Cancer, Global, Characteristics of Ideal Drug which Satisfies the Unmet Needs of the Market, 2010 123

Table 31: Prostate Cancer, Global, Description of Ideal Drug which Satisfies the Unmet Needs of the Market, 2010 124

Table 32: Prostate Cancer, Johnson & Johnson, Oncology Late Stage Pipeline by Indication, 2010 178

Table 33: Prostate Cancer, Global, Auron Healthcare, Key Pipeline Products, 2010 179

Table 34: Prostate Cancer, Global, M&A Deals by Geography, 2010 189

1.2 List of Figures

Figure 1: Prostate Cancer Therapeutics Market, Global, Treatment Guidelines, 2010 19

Figure 2: Prostate Cancer Therapeutics Market, Germany, Sales Value ($m), 2001-2009 20

Figure 3: Prostate Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2001-2009 21

Figure 4: Prostate Cancer Therapeutics Market, Germany, Patient Volume (’000s), 2001-2009 23

Figure 5: Prostate Cancer Therapeutics Market, Germany, Treatment Usage Patterns (’000s), 2001-2009 24

Figure 6: Prostate Cancer Therapeutics Market, Germany, Market Drivers and Restraints, 2009 26

Figure 7: Prostate Cancer Therapeutics Market, Germany, Historical Events Impact on the Market, 2010 28

Figure 8: Prostate Cancer Therapeutics Market, Germany, Sales Value ($m), 2009-2020 29

Figure 9: Prostate Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2009-2020 30

Figure 10: Prostate Cancer Therapeutics Market, Germany, Patient Volume (’000s), 2009-2020 31

Figure 11: Prostate Cancer Therapeutics Market, Germany, Treatment Usage Patterns (’000s), 2009-2020 32

Figure 12: Prostate Cancer Therapeutics Market, Germany, Future Market Drivers and Restraints, 2009-2020 34

Figure 13: Prostate Cancer Therapeutics Market, Germany, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2020 35

Figure 14: Prostate Cancer Therapeutics Market, Germany, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2020 37

Figure 15: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Chemotherapy Drugs, 2010 44

Figure 16: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Hormone Therapy Drugs, 2010 45

Figure 17: Prostate Cancer Therapeutics Market, Germany, Sales Forecast by Therapies, 2001-2020 46

Figure 18: Prostate Cancer, Global, Taxotere, Chemical Structure 48

Figure 19: Prostate Cancer, Global, Taxotere, LCM Activities, 2004-2010 49

Figure 20: Prostate Cancer, Germany, Taxotere, Sales ($m), 2004-2020 50

Figure 21: Prostate Cancer, Global, Casodex, Chemical Structure 51

Figure 22: Prostate Cancer, Global, Casodex, LCM Activities, 2004-2010 54

Figure 23: Prostate Cancer, Germany, Casodex, Sales ($m), 2001-2020 55

Figure 24: Prostate Cancer, Global, Zoladex, Chemical Structure 56

Figure 25: Prostate Cancer, Germany, Zoladex, Sales Forecast ($m), 2001-2020 57

Figure 26: Prostate Cancer, Global, Eligard , Chemical Structure 58

Figure 27: Prostate Cancer, Germany, Leuprolide (Eligard), Sales Forecast ($m), 2001-2020 61

Figure 28: Prostate Cancer, Global, Firmagon, Chemical Structure 62

Figure 29: Prostate Cancer, Germany, Firmagon, Sales Forecast ($m), 2008-2020 64

Figure 30: Prostate Cancer, Global, Novatrone, Chemical Structure 64

Figure 31: Prostate Cancer, Germany, Mitoxantrone, Sales Forecast ($m), 2001-2020 66

Figure 32: Prostate Cancer, Global, Emcyt, Chemical Structure 67

Figure 33: Prostate Cancer, Germany, Estramustine, Sales Forecast ($m), 2001-2020 67

Figure 34: Prostate Cancer, Global, Trelstar, Chemical Structure 68

Figure 35: Prostate Cancer, Global, Eulexin, Chemical Structure 69

Figure 36: Prostate Cancer, Global, Delestrogen, Chemical Structure 71

Figure 37: Prostate Cancer, Global, Gynodiol, Chemical Structure 72

Figure 38: Prostate Cancer, Global, Estrace, Chemical Structure 73

Figure 39: Prostate Cancer, Global, Tace, Chemical Structure 74

Figure 40: Prostate Cancer, Global, Nilandrone, Chemical Structure 74

Figure 41: Prostate Cancer, Global, Premarin, Chemical Structure 75

Figure 42: Prostate Cancer, Germany, Combined sales of Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol, Sales Forecast ($m), 2001-2020 76

Figure 43: Prostate Cancer, Global, Clinical Trials by Therapy, 2010 77

Figure 44: Prostate Cancer, Global, Clinical Trials by Phase of Development, 2010 78

Figure 45: Prostate Cancer, Global, Pipeline by Mechanism of Action, 2010 79

Figure 46: Prostate Cancer, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010 80

Figure 47: Prostate Cancer, Global, Technology Trends Description of Pipeline Drugs, 2010 81

Figure 48: Prostate Cancer, Global, Licensing Agreements by Phase of Development, 2009-2010 82

Figure 49: Prostate Cancer, Global, Licensing Agreements by Geography, 2010 85

Figure 50: Prostate Cancer, Germany, Provenge, Sales Forecast ($m), 2009-2020 89

Figure 51: Prostate Cancer, Germany, Jevtana, Sales Forecast ($m), 2001-2020 91

Figure 52: Prostate Cancer, Global, Aflibercept, Chemical Structure 92

Figure 53: Prostate Cancer, Germany, Aflibercept, Sales Forecast ($m), 2009-2020 93

Figure 54: Prostate Cancer, Germany, Ipilimumab , Sales Forecast ($m), 2009-2020 95

Figure 55: Prostate Cancer, Global, Abiraterone, Chemical Structure 96

Figure 56: Prostate Cancer, Germany, Abiraterone, Sales Forecast ($m), 2009-2020 98

Figure 57: Prostate Cancer, Global, Zibotentan, Chemical Structure 99

Figure 58: Prostate Cancer, Germany, Zibotentan , Sales Forecast ($m), 2009-2020 100

Figure 59: Prostate Cancer, Germany, Sprycel , Sales Forecast ($m), 2009-2020 102

Figure 60: Prostate Cancer, Global, MDV3100, Chemical Structure 103

Figure 61: Prostate Cancer, Germany, MDV3100 , Sales Forecast ($m), 2009-2020 104

Figure 62: Prostate Cancer, Global, Median Overall Survival for Hormone-independent Metastatic Prostate Cancer Patients, 2010 117

Figure 63: Prostate Cancer, Global, Median Overall Survival for Hormone-dependent Metastatic Prostate Cancer Patients, 2010 118

Figure 64: Prostate Cancer, Global, Hormone-dependent Metastatic Prostate Cancer Patients Achieving Castrate Level Testosterone Level in 28-30 Days (%), 2010 118

Figure 65: Prostate Cancer, Germany, Prostate Cancer, Opportunity and Unmet need, 2010 119

Figure 66: Prostate Cancer, Germany, Hormone-independent Metastatic Prostate Cancer, Opportunity and Unmet need, 2010 122

Figure 67: Prostate Cancer, Germany, Hormone-dependent Metastatic Prostate Cancer, Opportunity and Unmet need, 2010 123

Figure 68: Prostate Cancer, Global, Key Events Impacting the Future Market 125

Figure 69: Prostate Cancer, Germany, Implications for Future Market Competition, 2010 126

Figure 70: Prostate Cancer, Global, Future Players in the Market, 2010 128

Figure 71:Prostate Cancer, Sanofi-aventis, Major Pharmaceutical Drugs 2010 129

Figure 72: Prostate Cancer, Sanofi-aventis Pasteur, Diseases under each Vaccination Area 2010 130

Figure 73: Prostate Cancer, Global, Sanofi-aventis, SWOT Analysis, 2010 131

Figure 74: Prostate Cancer, Sanofi-aventis, Therapeutic Segment Share of Pipeline 2010 136

Figure 75: Prostate Cancer, Global, Pfizer, SWOT Analysis 2010 138

Figure 76: Prostate Cancer, Pfizer, Distribution of Pipeline by Phase, 2010 144

Figure 77: Prostate Cancer, Pfizer, Therapeutic Segment Share of Pipeline 2010 145

Figure 78: Prostate Cancer, Astrazeneca, Key Products Portfolio 2010 146

Figure 79: Prostate Cancer, Global, AstraZeneca, SWOT Analysis 2010 147

Figure 80: Prostate Cancer, AstraZeneca, Oncology Products for different Cancers 2010 151

Figure 81: Prostate Cancer, AstraZeneca, Distribution of Pipeline, by Phase, 2010 151

Figure 82: Prostate Cancer, AstraZeneca, Therapeutic Segment Share of Pipeline 2010 152

Figure 83: Prostate Cancer, Bristol-Myers Squibb, Key Products Portfolio 2010 153

Figure 84: Prostate Cancer, Global, Company Bristol-Myers Squibb, SWOT Analysis, 2010 154

Figure 85: Prostate Cancer, Bristol-Myers Squibb, Distribution of Pipeline by Phase, 2010 159

Figure 86: Prostate Cancer, Bristol-Myers Squibb, Therapeutic Segment Share of Pipeline 2010 160

Figure 87: Prostate Cancer, Global, Medivation, SWOT Analysis 2010 161

Figure 88: Prostate Cancer, Global, Takeda Pahrmaceuticals, SWOT Analysis 2010 165

Figure 89: Prostate Cancer, Global, Dendreon Corporation, SWOT Analysis 2010 167

Figure 90: Prostate Cancer, Global, Johnson and Johnson, SWOT Analysis 2010 172

Figure 91: Prostate Cancer, Johnson & Johnson, Late Stage Pipeline by Therapy Area, 2010 178

Figure 92: Prostate Cancer, Global, GlaxoSmithKline, SWOT Analysis 2010 181

Figure 93: Prostate Cancer, GlaxoSmithKline, Distribution of Pipeline by Phase, 2010 187

Figure 94: Prostate Cancer, GlaxoSmithKline, Therapeutic Segment Share of Pipeline 2010 188

Figure 95: Prostate Cancer, Global, M&A Deals by Geography of Target Companies, 2010 193

Figure 96: Prostate Cancer, Global, M&A Deals by Deal Size, 2010 193

Figure 97: Prostate Cancer, Germany, Key Data Inputs from KOL Interviews, July 2010 194

Figure 98: GlobalData Market Forecasting Model 200

Companies mentioned

Pfizer inc.

Takeda Pharmaceuticals

Auron Healthcare GmbH

Oncogenex Pharmaceuticals, inc.

GTx, inc.

To order this report:

Drug and Medication Industry: Prostate Cancer – Germany Drug Forecasts and Treatment Analysis to 2020

Drug and Medication Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Intl: +1 805-652-2626